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Summary: Serum cathepsin B-like activity was determined in 75 patients with ovarian carcinomas and in control
groups. Ovarian cancers were of FIGO stages I-IV. Control groups consisted of 15 healthy women, 20 patients
with myomas of the uterus, and 17 with benign ovarian cysts. Preoperative results showed elevated cathepsin B-
like activity in 100% of the patients with ovarian cancers in relation to healthy subjects and patients with myomas,
and in 78% in relation to benign ovarian cysts. Cathepsin B activity increased progressively with the FIGO stage
of the disease, but the differences among particular stages were not statistically significant. In serous tumours
cathepsin activity was significantly higher only in comparison to endometrioid ones (p < 0.001). Antipapain capac-
ity of cystatins in the sera was also determined. No significant correlation between cathepsin B-like, and antipapain
activity of cystatins was found. Serum cathepsin B-like activity may be helpful in the preoperative differential
diagnosis between ovarian carcinomas and benign ovarian or uterine tumours.
Introduction
Epithelial ovarian cancer, which is the major cause of
death among women with gynaecologic malignancies,
produces no readily identifiable or measurable sub-
stances that might be useful in the early detection or
management of the disease. These are imperative for ef-
fective treatment (1).
In an attempt to promote earlier diagnosis and improve
monitoring of ovarian cancer, numerous markers have
been studied (2—6). To date, none has been found suit-
able for widespread clinical application.
Pietras et al. (7) have suggested that a cysteine pepti-
dase, cathepsin B1), is a sensitive marker for ovarian
cancer diagnosis and may be of value in monitoring the
course of the disease. These conclusions, based on small
number of patients, seemed interesting enough to be ver-
ified.
Lysosomal cathepsin B, and its extracellularly secreted
as well as plasma membrane-associated forms for which
the name cathepsin B-like is often used, received great
interest regarding their role(s) in biochemical processes
underlying tumour growth, invasiveness, and metasta-
sis (8).
The aim of the present study was to examine cathepsin
B-like activity in sera of patients with ovarian cancer
under aspects of diagnostic value of the enzyme. More-
over, we wanted to find out if there is any correlation
(dependence?) between cathepsin B, and its specific in-
hibitors — cystatins.
Materials and Methods
Patients
Patients attending the Clinic of Obstetrics and Gynaecology, Wroc-
law University of Medicine, in 1989-1994 were the subject of this
study. The group with malignant tumours of the ovaries included
Tab. 1 Classification of ovarian cancers according to histopatho-
logical types and FIGO stages.
Histological types Disease stage Total %
I II III IV
Serous
Mucinous
Endometrioid
Undifferentiated
Clear cell
Other
Total
4
2
2
2
-
-
10
3
-
3
1
-
2
9
4
-
3
2
3
-
12
12
5
14
7
3
3
44
23
7
22
12
6
5
75
30.7
9.3
29.3
16.0
8.0
6.7
100
') Enzyme:
Cathepsin B (EC 3.4.22.1); papain (EC 3.4.22.2)
75 cases (tab. 1). The control groups consisted of 20 uterine myo-
mas, and 17 benign ovarian cysts (cystis simplex, cystadenoma,
cystis dermoidalis, cystis picea, cystis serosa, cystadenoma mu-
cinosum). The age at diagnosis was in the group of cancers 14—
82 (median 51 a) in the myomas, and cysts 35—60 (median 48 a),
respectively. In all the patients with ovarian or uterine tumours
laparotomy was performed. Ovarian tumour mass was removed
and the extent of the disease stage according to the FIGO classifi-
cation (9) was undertaken. Blood was taken before surgery from
patients suspected of having ovarian cancer. The blood samples
were centrifiiged and the serum stored at —20 °C until use (up to
2 months).
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Tab. 2 Preoperative serum cathepsin B-like and antipapain capacity of cystatin levels in patients
and controls.
Groups
Healthy women
Myomas of uterus
Benign ovarian cysts
Ovarian carcinoma
Stage I -IV
Stage I
Stage II
Stage III
Stage IV
N
15
20
17
75
10
9
12
44
Cathepsin B
(mU/1)
4.00
10.82
40.00
194.54
114.20
146.60
157.07
232.82
± 3.47
± 6.12
±31.15*
± 161.53*
± 40.30*
± 58.24*
± 72.77*
± 196.74*
Range
0.00-
0.00-
5.00-
25.30 -
68.50 -
25.30 -
46.65 -
34.80 -
9.5
21.00
97.32
880.40
203.50
200.10
268.10
880.40
Antipapain capacity of cystatins
(mU/1)
72.51
80.17
87.17
99.93
106.77
107.90
96.22
97.49
± 7.09
± 15.27
± 15.37*
± 25.32*
±25.14*
± 27.57*
± 17.37*
± 26.08*
Range
61.17-
61.17-
56.28 -
30.58 -
67.29 -
74.51 -
72.61 -
30.58 -
82.58
107.00
110.72
174.35
145.29
162.11
137.95
156.00
* Significantly different from: healthy control, myomas of the
uterus, and benign ovarian cysts (for cathepsin B-like activity
p < 0.001, for inhibitory capacity p < 0.01).
* Significantly different from: healthy control, and myomas of the
uterus (for cathepsin B-like activity p < 0.001, for inhibitory ca-
pacity p < 0.01).
The healthy control group, consisting of 15 healthy women at the
ages of 28—46 (median 39 a), was obtained from the Silesian Cen-
ter "Dolmed" in Wroclaw.
Methods
Cathepsin B-like activity in diluted (1 : 10) serum was performed
with the procedure described by Szego et al. (10) in 40 mmol/1
mixed sodium citrate/sodium phosphate buffer, pH 5.7 in the pres-
ence of 5 mmol/1 dithiothreitol and 0.17 mmol/1 substrate (carbo-
benzoxy-Ala-Arg-Arg-4-methoxy- -naphthylamide) in a total vol-
ume of 2 ml. After a 30 min incubation at 37 °C the reaction was
stopped by addition 0.5 ml of 0.1 mol/1 HC1. Fluorescence of the
reaction product was measured at the emission peak of 410 nm on
a Perkin-Elmer Fluorimeter LS-3 B with an activation beam of 292
nm. Fluorescence readings were standardized with 4-methoxy- -
naphthylamine. The results were expressed in mU/1 (one mU of
activity was defined as the amount of enzyme releasing 1 nmol of
4-methoxy- -naphthylamine per minute).
Antipapain activity of cystatine was measured after methylamine
inactivation of a2-macroglobulin, as described by Minakata et al.
(11), using caseine as a substrate and in the presence of 6 mmol/1
cysteine (12). Papain purchased from Calbiochem, USA, was tit-
rated with E-64 (Z,-epoxysuccinyl-leucylamido(4-guanidino)bu-
tane) to determine the active concentration of the enzyme (13).
One inhibitory unit was defined as the amount which inhibited
1 μπιοί of active papain completely. This was determined by ex-
trapolating the titration curves to zero papain activity.
As the upper normal limit (cut-off) of measured analytes we took
ovarian cysts mean value plus two standard deviations (SD). Statis-
tical analysis was performed using analysis of variance and the
unpaired Student's t-test. Linear regressions were computed using
the Pearson least-square method.
Results
Table 2 summarizes results of cathepsin B-like and anti-
papain activity of cystatin determinations in controls and
patient groups. Table 3 presents the percentage of the
results with value elevated above the cut-off values.
Such a limit value was calculated from the mean plus
two standard deviations measured in sera of patients
with benign ovarian cysts. In healthy women the serum
cathepsin activity ranged from 0.0 to 9.5 mU/1, in the
myoma patients from 0.0 to 21.0 mU/1, and in the benign
Tab. 3 Incidence of elevated cathepsin B-like activity and antipa-
pain activity of cystatins in sera of patients with benign and malig-
nant tumours.
Cut-off values are calculated from the results for the benign ovar-
ian cyst group (X + 2 SD).
Groups Cases with values above cut-off (%)
Cathepsin B Antipapain capacity
102.3 mU/1 of cystatins
117.91 mU/1
Healthy women
Myomas of uterus
Benign ovarian cysts
Ovarian carcinoma
Stage I-IV
Stage I
Stage II
Stage III
Stage IV
0.0
0.0
0.0
78.6
60.0
77.7
75.0
84.0
0.0
0.0
0.0
22.6
50.0
22.0
8.3
22.7
ovarian cysts 5.0 to 97.0 mU/1. The mean value of ca-
thepsin activity in malignant tumours was significantly
higher than in all the control groups examined
(p < 0.001). A wide dispersion of enzyme activity was
observed. Range of serum concentrations found for
ovarian cancer patients (25.3-880.4 mU/1) showed con-
siderable overlap with those found for benign ovarian
cysts patients. Serum levels of cathepsin B-like activity
in malignant rumours appear to increase progressively
with the stage of the disease. However, because of high
standard deviations, differences among groups were not
statistically significant. The incidence of elevated ca-
thepsin B-like activity concentrations above the cut-off
value (102.3 mU/1) was 60% in patients at stage I, and
84% at stage IV of the disease.
Analysis of the cathepsin B-like activity data in relation
to histological cancer types showed significantly higher
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activity in patients with serous tumours in comparison
to endometrioid types (p < 0.001) (data not shown).
Antipapain activity of cystatins was significantly raised
in the group of benign and malignant ovarian tumors as
compared with the healthy control group (tab. 2). The
incidence of concentrations elevated above the cut-off
value (117.9 mU/1) in the ovarian cancer groups ranged
from 8 (stage III) to 50% (stage I). Increase of antipa-
pain capacity was similar in all the histopathological
cancer types represented in the present study (data not
shown). A correlation coefficient equal to 0.2 between
serum cathepsin B-like, and antipapain activity of cys-
tatins was found.
Discussion
Though serum markers are of limited value in screening
the general population for ovarian cancer, they can be
used to assist the general gynaecologist in avoiding po-
tentially difficult oncologic surgery. Therefore, it is im-
portant that discrimination between benign and malig-
nant disease is made. Cathepsin B overexpression is
common to many malignant tumours (14). Elevated se-
rum activity or concentration was observed in patients
with breast (15), colorectal (16), gastric (17), laryngeal
(18), liver (19), and gynaecological (7, 20, 21) carcino-
mas.
We examined the usefulness of measuring serum cathep-
sin B-like activity in the preoperative discrimination of
ovarian carcinoma from benign tumours, and in the as-
sessment of the extent of the disease. Our study showed
elevated cathepsin B-like activity in 100% of the pa-
tients with malignant ovarian tumours in relation to
healthy women and those with myomas of the uterus,
and in 84% in relation to benign ovarian cysts. Pietras
et al. (7) demonstrated marked elevation in cathepsin B-
like activity in sera of patients with ovarian cancer of
FIGO stage III (+ 2490%) and IV (+ 3890%).
We also examined patients with stage I and II. The level
of cathepsin B-like activity in patients with stage I
(+ 1130%) and II (+ 1320%) was lower as related to
stage IV (+ 2190%). The results were expressed as per-
cent of elevation in relation to levels of enzyme activity
in women with myomas. When benign ovarian cysts
were used as a control the elevation was four times
lower. Benitez-Bribesca et al. (21) reported a significant
increase (p < 0.001) of cathepsin B activity in serum
and vaginal fluid of all patients with carcinoma of the
cervix uteri including that with stage 0 (carcinoma in
situ) in comparison to healthy women. In contrast, Ma-
karewicz et al. (20) who used a control group consisting
of patients with dysplasia have not found a rise of ca-
thepsin B-like activity in early disease limited to the
cervix uteri, while in early cervical carcinoma with me-
tastases to pelvic lymph nodes the activity was markedly
increased. Serum levels of the enzyme appear to
increase parallel to the activity in tumour tissue. Tissue
cytosol cathepsin B-like activity might also appear as a
useful independent prognostic marker for survival in hu-
man cancers including ovarian ones (14, 22). According
to the present study the sensitivity value of cathepsin B-
like serum level calculated using the benign ovarian
cysts group as a negative control is the same (64%) in
ovarian cancer as in cervical cancer, as described by
Makarewicz et al. (20). It is not known whether the ele-
vated activity of cathepsin B in serum is due only to its
elevated production either to secretion by tumour tissue
or to a disorder of its elimination from circulation or to
a derangement of its specific inhibitors (7, 19, 21).
Kininogens and cystatin C, together with a2-macroglob-
ulin, are believed to be the most potent extracellular in-
hibitors of lysosomal cysteine peptidases as well as pa-
pain, a model plant protease (23).
Alterations in the balance between endogenous cysteine
peptidase inhibitors, and cysteine peptidases have been
postulated to contribute to malignant progression (21,
23). This was why we explored a possible correlation
between serum cathepsin B-like activity and antipapain
capacity of cystatins which is mainly due to kininogens
(24). We measured the antipapain capacity after inacti-
vation of a2-macroglobulin with methylamine. The in-
hibitory capacity was elevated in 36% of patients with
ovarian cancer, which is consistent with our earlier ob-
servation (25). In spite of the low correlation coefficient
between cathepsin B-like and antipapain activity the
ratio of cathepsin activity to inhibitory activity rose from
0.08 in patients with myomas to 1.46 in patients with
ovarian cancer of FIGO stage IV.
It is concluded that the serum cathepsin B-like activity
determinations are helpful in the preoperative dif-
ferential diagnosis between ovarian carcinomas and be-
nign ovarian or uterine tumours.
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